Author: Qingyang Xu; Shomesh Chaudhuri; Danying Xiao; Andrew W Lo
Title: Bayesian Adaptive Clinical Trials for Anti-Infective Therapeutics during Epidemic Outbreaks Document date: 2020_4_14
ID: 20hk99h4_42
Snippet: Furthermore, as the proportion of the initially infected population decreases from 0.1% to 0.01% (Rows 4 to 6 of Table 3 ), the optimal sample sizes for non-adaptive and adaptive RCTs both increase, while the optimal Type I error rates decrease. Beginning the clinical trials for a therapeutic during the earlier stages of an epidemic outbreak reduces the need to expedite the approval process in order to contain its future spread. Clinicians and re.....
Document: Furthermore, as the proportion of the initially infected population decreases from 0.1% to 0.01% (Rows 4 to 6 of Table 3 ), the optimal sample sizes for non-adaptive and adaptive RCTs both increase, while the optimal Type I error rates decrease. Beginning the clinical trials for a therapeutic during the earlier stages of an epidemic outbreak reduces the need to expedite the approval process in order to contain its future spread. Clinicians and researchers have more time to evaluate the efficacy of a therapeutic and record adverse effects by testing it on a larger number of subjects, which leads to a lower Type I error rate.
Search related documents:
Co phrase search for related documents- approval process and early stage: 1
- approval process and epidemic outbreak: 1
- approval process and error rate: 1
- approval process and large number: 1
- approval process and optimal sample: 1, 2
- approval process and optimal sample size: 1, 2
- approval process and therapeutic clinical trial: 1, 2
- approval process and Type error rate: 1
- approval process expedite and clinical trial: 1
- approval process expedite and error rate: 1
- approval process expedite and optimal sample: 1
- approval process expedite and optimal sample size: 1
- approval process expedite and Type error rate: 1
Co phrase search for related documents, hyperlinks ordered by date